VTY

Ventyx

Stock
Stock
Ticker: VTYX
VTYX

Price

Price

CHART BY

Frequently asked questions

Ventyx's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -1.50. EPS indicates the company's profitability on a per-share basis.
Currently, 1 analysts cover Ventyx's stock, with a consensus target price of $14.00. Analyst ratings provide insights into the stock's expected performance.
Ventyx's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$115.10M. EBITDA measures the company's overall financial performance.
Ventyx has a free cash flow of -$87.87M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
Ventyx employs approximately 82 people. It operates in the Health Care sector, specifically within the Major Pharmaceuticals industry.

Financials

EPS (TTM) 
-1.50
EBITDA (TTM) 
-$115.10M
Free Cashflow (TTM) 
-$87.87M

Analyst Ratings

The price target is $14.00 and the stock is covered by 1 analysts.

Buy

0

Hold

1

Sell

0

Information

Ventyx Biosciences, Inc. engages in developing novel small molecule therapeutics for the treatment of autoimmune diseases. Its clinical stage pipeline includes VTX958, a Phase 1 allosteric TYK2 inhibitor for the treatment of a broad range of autoimmune diseases, VTX002, a Phase 2-ready S1P1 receptor modulator for the treatment of ulcerative colitis, and VTX2735, a Phase 1-ready peripheral inhibitor of the NLRP3 inflammasome, which is a mediator of multiple inflammatory conditions. The company was founded by Raju S. Mohan on November 21, 2018 and is headquartered in San Diego, CA.

Employees
82
Industries
Major Pharmaceuticals
Sector
Health Care

Identifier

Primary Ticker
VTYX

Knockouts

Real-time data from LSX · Fundamentals & EOD data from FactSet
Join the conversation